Clinical management of potential bioterrorism-related conditions

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 954-962

  Adalja, Amesh A ^a,b   Toner, Eric ^a,b   Inglesby, Thomas V ^a,b   Longo, Dan L ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BOTULINUM ANTISERUM; CIDOFOVIR; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SMALLPOX VACCINE; STREPTOMYCIN; TECOVIRIMAT;

ANTHRAX; ANTIBIOTIC SENSITIVITY; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; BOTULISM; CLINICAL FEATURE; CUTANEOUS ANTHRAX; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; FATALITY; GASTROINTESTINAL ANTHRAX; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS PNEUMONIA; LABORATORY DIAGNOSIS; LUMBAR PUNCTURE; MORTALITY; NONHUMAN; PLAGUE; PNEUMONIC PLAGUE; POPULATION RISK; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SMALLPOX; THORAX RADIOGRAPHY; TREATMENT PLANNING; TULAREMIA; VACCINATION; BACTERIAL INFECTIONS; DIFFERENTIAL DIAGNOSIS; UNITED STATES;

ANTHRAX; BACTERIAL INFECTIONS; BIOTERRORISM; BOTULISM; DIAGNOSIS, DIFFERENTIAL; HUMANS; PLAGUE; SMALLPOX; TULAREMIA; UNITED STATES;

EID: 84924502665     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1409755     Document Type: Review

References (48)

1. Mayor A. Greek fire, poison arrows and scorpion bombs: biological and chemical warfare in the ancient world. New York: Overlook Press, 2003.
2. Leitenberg M, Zilinskas RA. The Soviet biological weapons program: a history. Cambridge, MA: Harvard University Press, 2012.
3. Miller J, Engelberg S, Broad W. Germs: biological weapons and America's secret war. New York: Simon and Schuster, 2002.
4. Sell TK, Watson M. Federal agency biodefense funding, FY2013-FY2014. Biosecur Bioterror 2013; 11: 196-216.
5. Biological and chemical terrorism: strategic plan for preparedness and response: recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 2000; 49: (RR-4): 1-14.
6. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorismrelated anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8: 1019-28.
7. Christian MD. Biowarfare and bioterrorism. Crit Care Clin 2013; 29: 717-56.
8. Hanczaruk M, Reischl U, Holzmann T, et al. Injectional anthrax in heroin users, Europe, 2000-2012. Emerg Infect Dis 2014; 20: 322-3.
9. Martin GJ, Friedlander AM. Bacillus anthracis (anthrax). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2014.
10. Gastrointestinal anthrax after an animal- hide drumming event- New Hampshire and Massachusetts, 2009. MMWR Morb Mortal Wkly Rep 2010; 59: 872-7.
11. Sweeney DA, Hicks CW, Cui X, Li Y, Eichacker PQ. Anthrax infection. Am J Respir Crit Care Med 2011; 184: 1333-41.
12. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266: 1202-8.
13. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167: 1239-43.
14. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003; 36: 328-36.
15. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of antiprotective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44: 968-71.
16. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005; 5: 287-95.
17. Narayan SK, Sreelakshmi M, Sujatha S, Dutta TK. Anthrax meningoencephalitis- declining trends in an uncommon but catastrophic CNS infection in rural Tamil Nadu, South India. J Neurol Sci 2009; 281: 41-5.
18. Meaney-Delman D, Zotti ME, Rasmussen SA, et al. Anthrax cases in pregnant and postpartum women: a systematic review. Obstet Gynecol 2012; 120: 1439-49.
19. Bravata DM, Holty JE, Wang E, et al. Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Arch Pediatr Adolesc Med 2007; 161: 896-905.
20. Hupert N, Bearman GM, Mushlin AI, Callahan MA. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med 2003; 139: 337-45.
21. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014; 20(2): e130687.
22. Kayabas U, Karahocagil MK, Ozkurt Z, et al. Naturally occurring cutaneous anthrax: antibiotic treatment and outcome. Chemotherapy 2012; 58: 34-43.
23. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
24. Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361: 135-44.
25. Mytle N, Hopkins RJ, Malkevich NV, et al. Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother 2013; 57: 5684-92.
26. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144: 270-80.
27. Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300: 1532-43.
28. Wright JG, Plikaytis BD, Rose CE, et al. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine 2014; 32: 1019-28.
29. Ionin B, Hopkins RJ, Pleune B, et al. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol 2013; 20: 1016-26.
30. Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 8: 1124-32.
31. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008; 121: 1058-64.
32. Peterson BW, Damon IK. Orthopoxviruses: vaccinia (smallpox vaccine), variola (smallpox), monkeypox, and cowpox. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2014.
33. Smee DF. Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012. Future Virol 2013; 8: 891-901.
34. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010; 4: 71-9.
35. Food and Drug Administration. ACAM 2000 prescribing information (http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142572.pdf).
36. Centers for Disease Control and Prevention. Adverse reactions following smallpox vaccination (http://www.bt.cdc.gov/agent/smallpox/vaccination/reactions-vacc-clinic.asp).
37. Centers for Disease Control and Prevention. Medical management of smallpox (vaccinia) adverse reactions: vaccinia immune globulin and cidofovir (http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt-adv-reactions.asp).
38. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012; 206: 1372-85.
39. Frey SE, Winokur PL, Salata RA, et al. Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario. Vaccine 2013; 31: 3025-33.
40. Kennedy JS, Gurwith M, Dekker CL, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia- naive adults. J Infect Dis 2011; 204: 1395-402.
41. Mead PS. Yersinia species (including plague). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2014.
42. Mwengee W, Butler T, Mgema S, et al. Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania. Clin Infect Dis 2006; 42: 614-21.
43. Hodowanec A, Bleck TP. Botulism (Clostridium botulinum). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2014.
44. Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014; 209: 183-91.
45. Sobel J. Botulism. In: Luwick LI, Lutwick SM. Beyond anthrax: the weaponization of infectious diseases. New York: Humana Press, 2009.
46. Smith LA. Botulism and vaccines for its prevention. Vaccine 2009; 27: Suppl 4: D33-D39.
47. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep 2011; 60: 1454-5.
48. Penn RL. Francisella tularensis (tularemia). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier, 2014.